SEROBA LIFE SCIENCES FUND IV LIMITED PARTNERSHIP
Raised
$1M
Investors
2
Min Invest
$112,730
AltStreet Analysis
·Generated from EDGAR primary sources
Seroba Life Sciences Fund IV Limited Partnership is an Ireland-domiciled pooled investment fund that filed under Rule 506(b) and Section 3(c)(1) on 2023-10-26. The fund reported $1.0M raised from 2 investors with a minimum investment of $113K. This is a standalone filing with no matched parent platform in the AltStreet database.
This fund follows the typical exemption pattern for private investment vehicles—506(b) for capital formation and 3(c)(1) for Investment Company Act exclusion. The $113K minimum investment is accessible relative to many institutional alternative funds, though the offshore Ireland domicile suggests a cross-border structure common in life sciences venture investing.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
N/A SEROBA LIFE SCIENCES (GP IV) LIMITED
Executive Officer, Director · DUBLIN 2, L2
N/A SEROBA LIFE SCIENCES MANAGEMENT LIMITED
Executive Officer · DUBLIN 2, L2
PETER SANDYS
Director · DUBLIN 2, L2
ALAN O'CONNELL
Director · DUBLIN 2, L2
DANIEL O'MAHONY
Director · DUBLIN 2, L2
BRUNO MONTANARI
Director · DUBLIN 2, L2
ANDREW DUIGNAN
Executive Officer, Director · DUBLIN 2, L2
JENNIFER MCMAHON
Director · DUBLIN 2, L2
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
